FDA approves Johnson & Johnson's Rybrevant Faspro for EGFR lung cancer and expands TRUFILL use for chronic subdural hematoma ...
The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.
The FDA has approved the subcutaneous administration of a fixed combination of amivantamab (Rybrevant; Johnson & Johnson) and a recombinant human hyaluronidase for patients with non–small cell lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback